Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial

The Lancet 2026

View at publisher
Authors: Amy E. Colson, Anthony Mills, Moti Ramgopal, Christopher Bettacchi, Olayemi Osiyemi, Federico Hinestrosa, Gordon Crofoot, Harold Katner, Hiroyuki Gatanaga, Margaret Johnson, Tracy L. Diamond, Erika Barninger
+7 more Karen Eves, Feng-Hsiu Su, Yayun Xu, Stephanie O. Klopfer, Luisa M. Stamm, Michelle C Fox, Rima Lahoulou
DOI: 10.1016/s0140-6736(25)01948-8
Cited by: 17
References: 19

Fields of Study & Subjects

HIV/AIDS drug development and treatment HIV-related health complications and treatments HIV/AIDS Research and Interventions

Publication details

Journal / source
The Lancet
Publisher
Elsevier BV
Volume
407
Issue
10528
Pages
611–621
Publication date
1 February 2026
Language
EN